Novartis AG announced new US real-world analyses from its PRECISION platform evaluating Pluvicto (lutetium-177 vipivotide tetraxetan) in metastatic castration-resistant prostate cancer. In taxane-naïve, PSMA-positive patients previously treated with at least one androgen receptor pathway inhibitor, Pluvicto was associated with a median progression-free survival of 13.5 months, with longer median progression-free survival reported when used after one prior ARPI versus multiple ARPIs (15.8 vs. 12.7 months). Novartis said these studies, along with an analysis of treatment patterns in metastatic hormone-sensitive prostate cancer, will be presented at the ASCO Genitourinary Cancers Symposium on February 26, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240715OMX_____CNEWS_EN_GNW1001166330_en) on February 24, 2026, and is solely responsible for the information contained therein.